5-Bromo-2-cyclohexyl-1,3-thiazole | 1142195-61-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Bromo-2-cyclohexyl-1,3-thiazole
• CAS: 1142195-61-6
• 化学式: C₉H₁₂BrNS
• 分子量: 246.17
• InChiKey: IEPZESPMXKLXCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] RAD51 INHIBITORS<br/>[FR] INHIBITEURS DE RAD51
  申请人：CYTEIR THERAPEUTICS INC

  公开号：WO2020186006A1

  公开（公告）日：2020-09-17

  This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

  这项申请涉及由以下结构式（I）代表的RAD51抑制剂，以及它们的使用方法，例如用于治疗癌症、自身免疫疾病、免疫缺陷或神经退行性疾病。
• SUBSTITUTED ARYL COMPOUND
  申请人：Simcere Pharmaceutical Co., Ltd.

  公开号：EP4108663A1

  公开（公告）日：2022-12-28

  The present application describes a substituted aryl compound used as an RAD51 inhibitor and a pharmaceutically acceptable salt thereof. The compound has the structure as represented by Formula (I) and has the substituents and structural features as described in the present application. Furthermore, the present application describes a pharmaceutical composition containing the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof, and the use of the compound as represented by Formula (I) or the pharmaceutically acceptable salt thereof and the pharmaceutical composition containing same in the preparation of a drug for preventing or treating RAD51 mediated diseases.

  本申请描述了一种用作 RAD51 抑制剂的取代芳基化合物及其药学上可接受的盐。该化合物具有式（I）所代表的结构，并具有本申请中所描述的取代基和结构特征。此外，本申请还描述了一种含有式（I）所代表的化合物或其药学上可接受的盐的药物组合物，以及式（I）所代表的化合物或其药学上可接受的盐和含有该化合物的药物组合物在制备预防或治疗RAD51介导的疾病的药物中的用途。
• RAD51 INHIBITORS
  申请人：Cyteir Therapeutics, Inc.

  公开号：EP3681884B1

  公开（公告）日：2022-06-01
• [EN] METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER<br/>[FR] MÉTHODES POUR UTILISER DES INHIBITEURS DE RAD51 POUR LE TRAITEMENT DU CANCER DU PANCRÉAS
  申请人：CYTEIR THERAPEUTICS INC

  公开号：WO2020257752A1

  公开（公告）日：2020-12-24

  This application is directed to inhibitors of RAD51 represented by the following structural formula,; and methods for their use, such as to treat pancreatic cancer.